Skip to content
Peptidepedia

BPC-157 Side Effects: Safety Profile, Risks & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Side Effects

Preclinical animal studies have demonstrated a favorable safety profile for BPC-157, with no acute toxicity observed across multiple organ systems, including liver, spleen, lung, kidney, brain, thymus, prostate, and ovaries at doses ranging from 6 μg/kg to 20 mg/kg over 6-week periods.

However, human clinical safety data remains extremely limited. Anecdotal reports from users have included:

Commonly Reported:

  • Injection site pain, redness, or swelling
  • Mild dizziness
  • Nausea
  • Fatigue or drowsiness

Less Commonly Reported:

  • Anxiety or mood changes
  • Heart palpitations
  • Insomnia
  • Loss of appetite
  • Depression or anhedonia

The FDA has noted that BPC-157 may pose an immunogenicity risk (triggering an immune response). Additionally, because BPC-157 products are unregulated, contamination with other substances represents a significant concern, and some studies suggest that between 12% and 58% of ergo-nutritional supplements may be contaminated with other substances.

Frequently Asked Questions

Preclinical animal studies have shown no acute toxicity across multiple organ systems at various doses over 6-week periods. However, human clinical safety data are essentially nonexistent. The FDA has expressed concerns about potential immunogenicity and unknown long-term effects. Additionally, unregulated manufacturing creates contamination risks.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.
  2. Sikiric P, et al. Multifunctionality and Possible Medical Application of the Pentadecapeptide BPC 157. Pharmaceuticals. 2025.
  3. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014.
  4. Examine.com. BPC-157: Research Breakdown.
  5. U.S. Anti-Doping Agency. BPC-157: Experimental Peptide Creates Risk for Athletes.
  6. World Anti-Doping Agency. The 2024 Prohibited List International Standard.
  7. ClinicalTrials.gov. PCO-02 - Safety and Pharmacokinetics Trial.
  8. Rupa Health. BPC 157: Science-Backed Uses, Benefits, Dosage, and Safety.
  9. Drip Hydration. The Wolverine Stack: Can BPC 157 and TB 500 Accelerate Injury Recovery?
  10. Preferred Regenerative Medicine. The BPC-157, TB-500, KPV & GHK-Cu Peptide Stack Guide.
  11. Sikiric P, et al. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. PubMed.
  12. Sikiric P, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide, Literature and Patent Review. PubMed.
←Read the full BPC-157 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”